Stephen Tomlinson to Mice, Inbred BALB C
This is a "connection" page, showing publications Stephen Tomlinson has written about Mice, Inbred BALB C.
Connection Strength
1.029
-
Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. J Heart Lung Transplant. 2021 10; 40(10):1112-1121.
Score: 0.168
-
Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy. Transplantation. 2017 04; 101(4):e75-e85.
Score: 0.125
-
Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation. 2015 Mar 31; 131(13):1171-80.
Score: 0.108
-
Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts. Circulation. 2013 Mar 26; 127(12):1290-9.
Score: 0.094
-
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol. 2008 Dec 01; 181(11):8068-76.
Score: 0.070
-
Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement. Cancer Res. 2007 Oct 01; 67(19):9535-41.
Score: 0.064
-
Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005 Sep; 115(9):2444-53.
Score: 0.056
-
The effect of dexamethasone on human mucin 1 expression and antibody-dependent complement sensitivity in a prostate cancer cell line in vitro and in vivo. Immunology. 2004 Mar; 111(3):291-7.
Score: 0.050
-
In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.
Score: 0.042
-
CBX8 exhibits oncogenic properties and serves as a prognostic factor in hepatocellular carcinoma. Cell Death Dis. 2019 01 18; 10(2):52.
Score: 0.035
-
Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells. JCI Insight. 2018 12 20; 3(24).
Score: 0.035
-
C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis. Mucosal Immunol. 2018 09; 11(5):1375-1385.
Score: 0.034
-
Surface Expression of TGF? Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer. Cancer Res. 2016 12 15; 76(24):7106-7117.
Score: 0.030
-
Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):6061-6.
Score: 0.024
-
The C5 convertase is not required for activation of the terminal complement pathway in murine experimental cerebral malaria. J Biol Chem. 2012 Jul 13; 287(29):24734-8.
Score: 0.022
-
CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res. 2011 Nov 11; 109(11):1290-301.
Score: 0.021
-
Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int. 2011 Feb; 79(3):331-9.
Score: 0.020
-
A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor. Virol J. 2010 Feb 09; 7:30.
Score: 0.019
-
Mouse complement receptor-related gene y/p65-neutralized tumor vaccine induces antitumor activity in vivo. J Immunol. 2004 Jul 01; 173(1):205-13.
Score: 0.013